Welcome to our dedicated page for Awakn Life Scien news (Ticker: AWKNF), a resource for investors and traders seeking the latest updates and insights on Awakn Life Scien stock.
This page provides a historical news archive for Awakn Life Sciences Corp. (formerly trading under the symbol AWKNF), a clinical-stage biotechnology company that focused on developing therapeutics targeting addiction, substance use disorders, and mental health disorders. The company’s releases describe a near-term focus on Alcohol Use Disorder (AUD) and trauma-related mental health conditions such as Post-Traumatic Stress Disorder (PTSD).
News items in this archive cover several key themes. Readers can review detailed updates on Awakn’s research and development programs, including AWKN-001, an investigational ketamine-based combination therapy for severe AUD in the UK, AWKN-002, a proprietary oral thin film formulation of esketamine for moderate to severe AUD in the U.S., and AWKN-SND-14, a pre-clinical program of serotonin, dopamine, and noradrenaline modulators for trauma-related mental health disorders. The archive also includes reports on preclinical findings in the aminoindane program, expansion of Phase 3 trial sites for AWKN-001, and regulatory interactions such as the positive outcome of a Pre-IND meeting with the U.S. Food and Drug Administration for AWKN-002.
Corporate and capital markets developments are also documented. Releases describe an unsecured credit facility intended to support working capital, a binding letter of intent and subsequent arrangement agreement with Graft Polymer (UK) plc (later Solvonis Therapeutics plc), shareholder and court approvals, and the completion of the transaction under which Solvonis acquired all of Awakn’s outstanding equity. The company reported that its common shares would be delisted from the Canadian Securities Exchange and OTCPink Market and that it applied to cease to be a reporting issuer in Canada.
Investors and researchers can use this news archive to trace how Awakn articulated its strategy, advanced its clinical and pre-clinical programs, and ultimately transitioned its assets and listing into Solvonis Therapeutics plc. Bookmarking this page allows users to revisit the historical sequence of announcements that shaped the evolution and eventual acquisition of Awakn Life Sciences Corp.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTCQB: RVLWF) has entered into a licensing partnership with Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF) to implement the KARE® protocol for treating Alcohol Use Disorder. Awakn's ketamine-assisted therapy demonstrates significant improvements over current treatment standards, achieving an 86% abstinence rate in post-treatment trials. Revitalist will incur an annual licensing fee and share revenue from services. The U.S. alcohol treatment industry, worth over $30B, faces high relapse rates, which this partnership aims to address.
FAQ
What is the current stock price of Awakn Life Scien (AWKNF)?
